| Affiliation: | (1) Department of Nuclear Medicine, University of Bonn, Germany, DE;(2) Department of Nuclear Medicine, University of Tübingen, Germany, DE;(3) Department of Nuclear Medicine, University of Cologne, Germany, DE;(4) Department of Nuclear Medicine, University of Münster, Germany, DE;(5) Department of Nuclear Medicine, University of Essen, Germany, DE;(6) Department of Nuclear Medicine, Medical School of Hannover, Germany, DE;(7) Department of Nuclear Medicine, Aachen University of Technology, Germany, DE |
| Abstract: | n =222) and the group with negative radioiodine scan (n=166), respectively. Specificity was 90% in the whole patient group. Sensitivity and specificity of WBS were 50% and 99%, respectively. When the results of FDG-PET and WBS were considered in combination, tumour tissue was missed in only 7%. Sensitivity and specificity of MIBI/Tl were 53% and 92%, respectively (n=117). We conclude that FDG-PET is a sensitive method in the follow-up of thyroid cancer which should be considered in all patients suffering from differentiated thyroid cancer with suspected recurrence and/or metastases, and particularly in those with elevated thyroglobulin values and negative WBS. Received 4 May and in revised form 11 June 1999 |
